Adagio Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
06 January 2022 - 10:30PM
Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of antibody-based solutions for infectious
diseases with pandemic potential, today announced that Tillman
Gerngross, Ph.D., chief executive officer of Adagio, is scheduled
to present at the 40th Annual J.P. Morgan Healthcare Conference on
Thursday, January 13, 2022 at 7:30 a.m. ET.
A live webcast will be available in the investor section of the
company's website at investors.adagiotx.com and will be archived
for 60 days following the presentations.
About Adagio Therapeutics
Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical
company focused on the discovery, development and commercialization
of antibody-based solutions for infectious diseases with pandemic
potential, including COVID-19 and influenza. The company’s
portfolio of antibodies has been optimized using Adimab’s
industry-leading antibody engineering capabilities and is designed
to provide patients and clinicians with the potential for a
powerful combination of potency, breadth, durable protection (via
half-life extension), manufacturability and affordability. Adagio’s
portfolio of SARS-CoV-2 antibodies includes multiple non-competing,
broadly neutralizing antibodies with distinct binding epitopes, led
by ADG20. Adagio has secured manufacturing capacity for the
production of ADG20 with third-party contract manufacturers to
support the completion of clinical trials and initial commercial
launch, if authorized or approved by regulatory authorities,
ensuring the potential for broad accessibility to people around the
world. For more information, please
visit www.adagiotx.com.
Contacts:
Media Contact:Dan Budwick,
1ABDan@1abmedia.com
Investor Contact:Monique Allaire, THRUST
Strategic Communicationsmonique@thrustsc.com
Adagio Therapeutics (NASDAQ:ADGI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adagio Therapeutics (NASDAQ:ADGI)
Historical Stock Chart
From Apr 2023 to Apr 2024
Real-Time news about Adagio Therapeutics Inc (NASDAQ): 0 recent articles
More News Articles